# Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

> **NCT06215651** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cadonilimab and Lenvatinib

## Interventions

- **DRUG:** Cadonilimab lenvatinib

## Key facts

- **NCT ID:** NCT06215651
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2025-01
- **Final completion:** 2027-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06215651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06215651, "Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06215651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*